Bengaluru-based real estate giant Puravankara Limited has welcomed Deepak Rastogi as their new Group Chief Financial Officer (CFO), set to take effect from January 15, 2025. This strategic move aims to enhance the company's financial controls and operatio
Real EstateCfoPuravankaraDeepak RastogiFinancial ManagementReal Estate NewsJan 07, 2025
Deepak Rastogi will take over as the Group CFO at Puravankara Limited effective from January 15, 2025.
Neeraj Gautam is currently the President of Finance at Puravankara Limited and will be elevated to the role of Deputy Chief Financial Officer.
Ashish Puravankara is the Managing Director of Puravankara Limited.
Deepak Rastogi is a Chartered Accountant and holds an MBA from the SP Jain Institute of Research & Management.
Deepak Rastogi has held leadership positions, including President & Group CFO at Deepak Fertilisers and Petrochemicals Ltd. and President & Group CFO at TATA Autocomp Systems Ltd.
China unveils a major support package to inject $562 billion into the property market and renovate a million homes, aiming to revive economic growth and address housing issues.
Danube Group, a leading UAE-based real estate developer, is set to expand its presence to Abu Dhabi and Ras Al-Khaimah, driven by interest from Indian investors.
The SEBI-registered Category II Alternative Investment Fund (AIF) aims to support pre-series A and series A stage startups in the real estate sector, addressing the growing need for innovation in the industry.
Morgan Stanley report highlights decline in investors' interest in real estate. Find out the reasons behind this trend.
Since its inception in 1996, Rustomjee Group has been a prominent player in Mumbai's real estate sector, with a portfolio spanning residential, commercial, and industrial projects. Dr. Rakesh Setia, the visionary leader, shares insights on how the company
The Indian stock market witnessed a significant plunge of over 1% today, driven by mixed economic cues. Key sectors such as real estate, public sector banks, metals, auto, and pharma experienced substantial declines, with the real estate sector being the